Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
205.44
-3.14 (-1.51%)
At close: Dec 5, 2025, 4:00 PM EST
206.00
+0.56 (0.27%)
After-hours: Dec 5, 2025, 5:55 PM EST
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 15 analysts that cover Ascendis Pharma stock have a consensus rating of "Strong Buy" and an average price target of $256.27, which forecasts a 24.74% increase in the stock price over the next year. The lowest target is $220 and the highest is $307.
Price Target: $256.27 (+24.74%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 7 | 6 | 6 |
| Buy | 10 | 10 | 10 | 10 | 9 | 9 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 16 | 16 | 17 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $220 | Buy | Reiterates | $220 | +7.09% | Nov 18, 2025 |
| Raymond James | Raymond James | Strong Buy Initiates $271 | Strong Buy | Initiates | $271 | +31.91% | Oct 17, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $203 → $254 | Buy | Maintains | $203 → $254 | +23.64% | Oct 13, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $260 → $264 | Buy | Maintains | $260 → $264 | +28.50% | Oct 9, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $227 → $230 | Strong Buy | Maintains | $227 → $230 | +11.95% | Sep 2, 2025 |
Financial Forecast
Revenue This Year
726.32M
from 363.64M
Increased by 99.74%
Revenue Next Year
1.30B
from 726.32M
Increased by 79.40%
EPS This Year
-3.22
from -6.53
EPS Next Year
3.16
from -3.22
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 764.9M | 1.5B | ||||
| Avg | 726.3M | 1.3B | ||||
| Low | 668.9M | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 110.4% | 108.0% | ||||
| Avg | 99.7% | 79.4% | ||||
| Low | 83.9% | 44.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.95 | 6.38 | ||||
| Avg | -3.22 | 3.16 | ||||
| Low | -3.69 | -0.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.